Last reviewed · How we verify
Id-KLH
At a glance
| Generic name | Id-KLH |
|---|---|
| Also known as | Vacmun KLH |
| Sponsor | Favrille |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Idiotype Vaccine After Chemotherapy & Stem Cell Transplantation in Lymphoma With Failed Induction Chemotherapy (NA)
- KLH Challenge to Explore the Human Immune Response (NA)
- Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant (PHASE2)
- Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant (PHASE1)
- Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation (PHASE1)
- Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (PHASE2)
- Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (PHASE2)
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Id-KLH CI brief — competitive landscape report
- Id-KLH updates RSS · CI watch RSS
- Favrille portfolio CI